The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

NCT02501850 on ClinicalTrials.gov · last registry update 2015-07-21

40 participants. Its estimated completion date, July 2015, has passed with no update to the record. Primary outcome, as filed: Change in blood levels of Lipoprotein (a) (Lp(a)). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Sponsor type: Other
Enrollment: 40
Started: 2014-10
Primary completion: 2015-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in blood levels of Lipoprotein (a) (Lp(a))

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.